NCT01255423已完成3 期
A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 206
- 主要终点
- Pain on Movement
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains under 'in-use' conditions, in particular with regard to pain relief.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Diclofenac sodium topical gel 1%
Experimental
干预措施: Diclofenac sodium topical gel 1% (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Pain on Movement
时间窗: 72 hours
Pain on movement at 72 hours assessed on a 100 mm visual analog scale with anchors at 0= "No pain" and 100= "Extreme pain"
次要结局
- Pain on Movement(24 hours and 7 days)
- Onset of Pain Relief(Day 1)
- Tenderness(Change from baseline at 24 and 72 hours, 7 days)
- Ankle Joint Function(24 and 72 hours, 7 days)
研究者
相似试验
已完成
4 期
Acute Low Back Pain. Topical Diclofenac and Oral Ibuprofen.Low Back PainNCT04611529Montefiore Medical Center198
已完成
4 期
Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck PainNeck PainNCT01335724Novartis72
已完成
4 期
Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint PainAnkle SprainNCT01666197Novartis100
已完成
3 期
Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the KneeOsteoarthritisNCT02121002Amneal Pharmaceuticals, LLC1,176
终止
4 期
Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract InfectionsFeverNCT01019980Novartis Pharmaceuticals2
